Suven allots 1.85 cr shares on warrant conversion; sets up Singapore WOS
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 0.2 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved conversion of 1,85,70,133 warrants into equity shares at Rs 134 each to 17 non-promoter allottees, raising about Rs 248.84 crore. Paid-up equity capital rose to 28.26 crore shares. Also re-appointed Dr. Vajja Sambasiva Rao as Independent Director for 5 years from Jan 2027. Incorporated wholly owned subsidiary Suven Neurosciences Pte. Ltd. in Singapore with planned investment of USD 100 million for neurological therapeutics.
Dilution from warrant conversion already priced in. Fresh capital strengthens balance sheet; Singapore WOS signals overseas push into neuro therapeutics.